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Peptidoglycan (PG) is the major component of the cell wall of gram-positive bacteria. In
vitro, PG isolated from conventional bacterial cultures can induce secretion of proinflam-
matory cytokines by human monocytes, indicating that PG may be involved in immune
responses against infections by gram-positive bacteria. To investigate the biologic activity of
PG in human tissues, an improved method was developed to isolate significant amounts of
PG from sterile human spleen tissue. Biochemical analysis demonstrated that PG isolated
from human spleen is largely intact. Human whole blood cell cultures were able to produce
the proinflammatory cytokines tumor necrosis factor-a and interleukin-1 and -6 after stim-
ulation with PG isolated from human spleen. Cytokine induction was not sensitive to inhi-
bition by polymyxin B, in contrast to lipopolysaccharide. Collectively, the data show that
intact PG in sterile human tissue is biologically active and may induce local proinflammatory
cytokine production.
Peptidoglycan (PG) is the major component of the cell wall
of gram-positive bacteria. PG is composed of alternating N-
acetyl glycosamine (GlcNAc) and N-acetyl muramic acid
(MurNAc) long sugar chains that are interlinked by peptide
bridges resulting in a large complex macromolecular structure
[1]. During bacterial infection, PG and several other cell wall
components are thought to be involved in the in¯ammatory
reaction [2]. In gram-negative infections, lipopolysaccharide
(LPS) is a well-known activator of the innate immune system
[3, 4]. During gram-positive infections, when no endotoxin is
present, PG can activate complement [5, 6] and granulocytes
[7, 8] and also up-regulate expression of adhesion molecules on
endothelial cells [8]. Of importance, PG can also induce pro-
duction of proin¯ammatory cytokines such as interleukin (IL)-
1 and -6 and tumor necrosis factor (TNF)-a by monocytes in
vitro [9, 10]. Similar to LPS-induced cytokine production, in-
hibition can be achieved by preventing uptake of PG and/or
activation of macrophages and monocytes by blocking the
CD14 receptor [11, 12].
In addition to the role of PG in gram-positive infections, it
has been hypothesized that PG is involved in the pathogenesis
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of chronic in¯ammation such as rheumatoid arthritis [13±15].
We are interested in the relationship between PG derived from
the normal intestinal ¯ora and the pathogenesis of rheumatoid
arthritis [16, 17]. The presence of PG in relevant tissues is a
prerequisite for this relationship. Most studies investigating the
presence of PG in human tissues focus on the detection of
muramic acid, the characteristic amino sugar in the glycan
backbone of PG, which can be detected after release of the N-
acetyl group of MurNac by acid hydrolysis. Furthermore, ra-
diolabeled PG has been used to study the localization of PG
in vivo. With these different techniques, PG was detected in
liver and spleen [18, 19], synovial tissues [18, 19], urine [20],
synovial ¯uid [21], and peripheral blood leukocytes [22]. We
detected PG in dendritic cells and macrophages of normal hu-
man spleen and synovial tissues of rheumatoid arthritis patients
[23] by use of a monoclonal antibody (MAb) directed against
bacterial ¯ora±derived PG isolated from human feces [24]. We
also isolated PG from normal human spleen with biochemical
methods [25].
The presence of PG in human tissues other than the gastro-
intestinal tract suggests that the body is constantly exposed to
bacterial products, even in the absence of clinically apparent
infection. PG in human tissues is probably derived from the
normal gut ¯ora. Experiments in rats have shown that PG can
be absorbed from the bowel wall [26].
All studies to determine the biologic activity of PG have
focused on PG isolated from bacterial cultures. Thus far the
biologic properties of PG in human tissues have never been
studied. Therefore, the aim of this study was to determine
whether PG in sterile human tissues has the capacity to induce
production of proin¯ammatory cytokines by human peripheral
blood mononuclear cells. To this end, we developed an im-
proved method to isolate high amounts of structurally intact
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PG with minimal traces of contaminating protein from sterile
human spleen tissue. Biological activity of this PG fraction was
determined by analysis of its ability to induce production of
proin¯ammatory cytokines by human blood cells.
Materials and Methods
Spleens used for isolation of PG. Seven un®xed human spleens
were obtained from the pathology department immediately after
surgery (SSDZ, Delft, The Netherlands) and kept frozen (2207C)
until use. Spleens were removed for surgical technical reasons from
3 patients with gastric carcinoma and from 4 patients because of
splenomegaly due to hematologic diseases. Spleen samples were
aerobically and anaerobically cultured on blood agar base (Oxoid,
London) for 48 h at 377C. The anaerobic plates were cultured in
a jar with gaspack generator envelopes with palladium catalyst
(Becton Dickinson, San Jose, CA). Bacterial growth was not ob-
served, con®rming that no bacteremia in vivo or contamination of
the tissue after surgery had occurred.
Immunohistochemistry for detection of PG in spleen. To deter-
mine whether the spleens obtained to isolate PG contained PG in
antigen-presenting cells, immunohistochemical staining of frozen
sections was done according to the method of Kool et al. [24] for
staining of rat spleen. We used the same MAb (2E9; mouse IgG3)
recognizing human intestinal ¯ora-derived PG.
PG isolation from human feces. PG from feces of a healthy
subject was prepared as described previously [27]. In brief, feces
were diluted in distilled water (40 g in 100 mL) and homogenized
in a laboratory blender (model 400; Stomacher, Colworth, UK).
After cambric gauze ®ltration, the suspension was centrifuged for
45 min at 5000 g. Four volumes of 96% ethanol were added to 1
vol of supernatant, and after 2 h at 47C the precipitate was cen-
trifuged for 15 min at 5000 g. The pellet was dissolved in and
dialyzed against Milli-Q water (Millipore, Bedford, MA) for 48 h.
Next, the suspension was centrifuged for 1 h at 100,000 g, and the
clear supernatant was collected. Size-exclusion chromatography
was done using dilutions of 15±60 mg/30 mL (depending on the
viscosity of the solution) with a TSK HW75 column (Merck, Darm-
stadt, Germany; gel bed 7003 eluent). After passage of 100 mL
of void volume, fractions (8 mL/5 min) were collected and assayed
for their protein and carbohydrate contents. High-molecular-
weight fractions containing carbohydrates but no proteins were
pooled, dialyzed, and lyophilized. From 100 g of feces, ∼50 mg of
PG could be retrieved by this procedure.
PG isolation from human spleen. Some 50±100 g of minced
spleen tissue in 500±1000 mL Milli-Q water was homogenized in
portions in a homogenizer (Virtis, New York) at 10,000 rpm for
30 s. The homogenate was sonicated 5 times for 1 min at maximum
amplitude (soniprep 150; MSE, Crawley, UK). Acetic acid (96%)
was added to a ®nal concentration of 0.2 M. The extract was
incubated at room temperature for 2 h under rotation and was
subsequently heated gradually in a water bath by 1007C over 30
min. The extract was centrifuged at 10,000 g for 60 min (47C). The
volume of the supernatant was reduced by lyophilization to 25±50
mL, and the extract was then centrifuged at 100,000 g for 60 min
(47C). The supernatants were separated by gel ®ltration on a 275-
mL gel bed (Sephadex G-25; Pharmacia, Uppsala, Sweden). Mur-
amic acid and protein content were determined in all fractions
according to the methods of Hadzija [28] (with modi®cations [29])
and Bradford [30], respectively. The high-molecular-weight fraction
containing muramic acid was collected, and size exclusion was done
by loading 1-mL fractions on a Superdex 200 column (Pharmacia)
connected to a fast performance liquid chromatograph (FPLC;
Pharmacia). Protein was determined in all fractions according to
Bradford [30], and PG was measured by ELISA. Fractions were
pooled (see below), dialyzed against Milli-Q water, and lyophilized.
Analysis of PG Isolated from Human Spleen
PG detection by ELISA. To measure PG in the fractions after
Superdex 200 (Pharmacia) gel ®ltration, an ELISA was performed.
We coated 50 mL of the fractions overnight at 507C in 96-well
polystyrene microtiter plates. The plates were washed 3 times with
PBS-0.02% Tween 20 (Fluka Chemie, Buchs, Switzerland), and 100
mL of MAb 2E9 (10 mg/mL in PBS-0.2%Tween) was added to the
wells. After 1 h at 377C, unbound antibody was removed by 3 wash
steps. As detecting antibody, we used peroxidase-conjugated rabbit
anti-mouse immunoglobulin (P260; Dako, Glostrup, Denmark) di-
luted 1:1000 in PBS-Tween 0.2%. After 3 washes, the colorimetric
assay was developed at 377C for 30±45 min after the addition of
100 mL of ortho-phenylenediamine/H2O2. The reaction was stopped
by the addition of 50 mL of 4 M H2SO4, and the optical density
was measured at a wavelength of 492 nm (Titertek Multiskan; Flow
Laboratories, Irvine, UK). Results were expressed as optical den-
sity units.
Protein analysis according to the method of Lowry et al. [31].
The amount of protein in the pooled fractions was determined by
the method of Lowry et al. [31], with modi®cations [32]. We added
1 mL of 2% Na2CO3 in 0.1 M NaOH to 200 mL of the pooled
fractions and incubated it for 45 min at 707C. After the samples
were cooled, 20 mL of 0.5% CuSO4.5H2O was added, and the mix-
ture was incubated for 10 min at room temperature. Finally, 200
mL of Folin-Ciocalteen reagent was added during 45 min at 377C.
Absorbance was measured at 620 nm.
Muramic acid analysis by colorimetric muramic acid assay.
In the pooled fractions, the amount of muramic acid was deter-
mined in accordance with the Hadzija method [28] with some mod-
i®cations [29]. In short, 100 mL of the samples was hydrolyzed by
heating for 2 h at 907C with an equal volume of 5 M H2SO4, then
neutralized with 100 mL 10 M NaOH. Hydrolyzed and unhydro-
lyzed samples (100 mL) were incubated with 50 mL 1 M NaOH at
377C for 30 min. After the addition of 1 mL 18.8 M H2SO4, samples
were heated for 3.5 min at 1007C, rapidly cooled on ice, and mixed
with 10 mL 0.16 M CuSO4.5H2O in H2O and 20 mL 0.09 M r-
hydroxydiphenyl in ethanol. After incubation for 30 min at 307C,
absorbance at 570 nm was determined by Titertek Multiskan. So-
lutions containing 0±100 mg of muramic acid (Sigma, St. Louis)
per milliliter of H2O were used as standards. The data are given
as the difference in concentration between the hydrolyzed and non-
hydrolyzed samples. In this way, only muramic acid linked to pep-
tides in PG was determined, and contaminating sugars like rham-
nose and lactic acid, which are determined in the nonhydrolyzed
sample, were excluded.
Muramic acid assay by high performance liquid chromatography
(HPLC). The presence of muramic acid in the isolated fraction
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Figure 1. Detection of cells containing PG in human spleen. Im-
munohistochemical staining used 2E9. Morphology and anatomic lo-
calization of cells containing intracytoplasmatic PG is consistent with
that of antigen-presenting cells. Magni®cation 363.
was also determined by amino sugars using HPLC reversed-phase
techniques as described by Glauner [33]. In short, 300 mL of the
isolated PG was hydrolyzed with 9 M HCl for 3 h at 907C. The
sample was frozen, lyophilized, and redissolved in 100 mL of H2O.
This sample was added to 100 mL 200 mM borate buffer, pH 8.8,
and 100 mL 20 mM dansyl chloride (5-dimethylamino-naphthalene-
1-sulfonyl chloride; Fluka Chemie) in acetone for 2 h at 377C. The
reaction was stopped with 35 mL 200 mM phosphoric acid.
Separation of dansylated amino acids and amino sugars was
accomplished by reversed-phase HPLC. Samples were analyzed
using a single pump solvent delivery system (LAB 2248; Pharmacia)
and a UV-VIS 2141 monitor (Pharmacia), both connected to a
computer working with HPLC manager software to control the
pump, gradient mixer, and UV-VIS detector operating at 330 nm.
Integration and analysis of chromatograms was done using the
same software (Pharmacia). Dansylated samples were separated by
use of a 5-mm nm column (SuperPac Sephacil C18; Phar-4 3 250
macia). The ¯ow rate was 1 mL/min, and the two buffers were as
follows: buffer A, 20 mM sodium phosphate, pH 5.25; and buffer
B, 60% acetonitrile and 40% 50 mM sodium phosphate, pH 4.0.
At 0, 10, 16, and 22 min, the concentration of buffer B was 30%,
50%, 100%, and 30%, respectively. Eluted products were detected
at 330 nm, the wavelength that is maximally absorbed by the dansyl
groups.
Induction of cytokine release in whole blood after stimulation with
PG. Human peripheral blood was obtained from healthy donors
and collected in sodium-heparin tubes (Vacutainer; Becton Dick-
inson). We added 12.5 mL of RPMI 1640 (Gibco, Breda, The Neth-
erlands) containing isolated PG or LPS (Sigma) with or without
the LPS antagonist polymyxin B (10 mg/mL; Sigma) to a polypro-
pylene tube (Falcon; Becton Dickinson) containing 112.5 mL of
blood. Inhibition assays were performed by incubation of human
blood cells with 10 and 5 mg/mL anti-CD14 antibody (My-4, azide-
free clone; Coulter, Hialeah, FL) or isotype control IgG2b antibody
(MOPC-195 clone; Coulter) for 30 min at 377C or by incubation
of the isolated PG fractions and LPS with proteases (1%±0.001%:
elastase, trypsin, a-chymotrypsin; Sigma) for 1 h at 377C. The
mixtures were incubated for 5 h at 377C in a 5% CO2 atmosphere,
then 375 mL of RPMI was added to each tube, and the mixtures
were centrifuged for 10 min at 400g. The supernatants were tested
in bioassays for TNF-a, IL-1, and IL-6 activity.
TNF-a bioactivity was measured using the murine ®broblast cell
line WEHI 164.13 in a cytotoxicity assay [34]. The cells were plated
in ¯at-bottom tissue plates with 96-well plates (Costar, Cambridge,
MA) at a concentration of 104 cells/well. The cells were allowed to
adhere by incubation overnight at 377C in a 5% CO2 atmosphere.
At day 2, 50 mL of actinomycin-D (4 mg/mL; Sigma) and 50 mL
of diluted sample were added to the cells. Samples were tested in
triplicate. After an overnight incubation (377C, 5% CO2), the MTT
(Sigma) cytotoxicity test [35] was used to measure WEHI cell
viability.
IL-1 bioactivity was measured by use of an IL-1±dependent sub-
line of the murine T cell line D10.G4.1, designated D10(N4)M, by
the method of Hopkins and Humphreys [36], with modi®cations
[37]. One hundred microliters of sample was added to 104 cells/
well, and the cells were cultured for 3 days. Proliferation of the
cells was measured after 4 h of [3H]thymidine incorporation (0.2
mCi/well).
IL-6 activity was detected by use of the murine hybridoma cell
line B9 according to Aarden et al. [38]. In the presence of 100 mL
of sample, cells/well were cultured for 3 days. Proliferation35 3 10
of IL-6±dependent B9 cells was measured after 4 h of [3H]thymidine
incorporation (0.2 mCi/well).
Recombinant human IL-1b (UBI, Lake Placid, NY), IL-6 (gift
of L.A. Aarden, CLB, Amsterdam), and TNF-a (Amersham,
Amersham, UK) served as positive controls for the D10, B9, and
WEHI assays. Cytokine activities of the samples were corrected
for background activity of cells cultured in the absence of PG and
were expressed as units per milliliter with 1 U corresponding to a
half-maximum response obtained with a titration series of the re-
combinant cytokine.
TNF-a ELISA. TNF-a production in anti-CD14 and protease
treatment experiments was measured by a capture ELISA that was
done following the manufacturer's guidelines (Biosource, Fleurus,
Belgium). In brief, polystyrene microtiter wells (Immuno maxisorp;
Nunc, Roskilde, Denmark) were coated overnight at room tem-
perature with human anti±TNF-a MAb, followed by a wash (0.9%
NaCl) and 2 h of blocking (PBS/BSA 0.5%). Freshly thawed sam-
ples and a human TNF-a standard (calibrated against WHO in-
ternational standard, TNF-a 87/650; National Institute for Bio-
logical Standards and Controls, Potters Bar, UK) were incubated
for 2 h in the presence of a biotinylated second TNF-a antibody,
followed by wash steps, polystreptavidine-HRP (CLB), and enzyme
substrate (TMB peroxidase; KPL, Gaithersburg, MD). Optical
density was measured at 450 nm.
Results
Immunohistochemical staining of human spleen. To con®rm
that antigen-presenting cells containing PG were present in hu-
man spleens to be used for puri®cation of PG, immunohisto-
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Figure 2. Separation of relatively high- and low-molecular-weight fractions from human spleen extract. Twenty-®ve milliliters of human spleen
extract was added to Sephadex G25 column. In all fractions, amount of protein (M) according to Bradford [30] and amount of muramic acid
(m) were measured. Fractions between 120 and 156 mL of elution volume, which represented relatively high-molecular-weight fraction containing
muramic acid, were pooled (↔).
chemical staining was done. With MAb 2E9 directed against
PG derived from the normal intestinal ¯ora, macrophages and
dendritic cells in all 7 spleens stained positive (®gure 1). With
a negative control antibody of the same isotype (mouse IgG3)
and with irrelevant speci®city (anti-sheep red blood cells), no
staining was found.
Isolation of PG from human spleen. The puri®cation of PG
from 7 individual human spleens was done as described. After
homogenization and sonication, the relatively low-molecular-
weight fraction was discarded by Sephadex G25 gel ®ltration.
Figure 2 shows the elution pattern after Sephadex G25 gel
®ltration of 1 human spleen. Protein was ®rst found after an
elution volume of 120 mL of H2O. Muramic acid was detected
after an elution volume of 124 mL of H2O until 156 mL. After
an elution volume of 156 mL of H2O, the signal for muramic
acid increased sharply due to the presence of lactate, which
interferes with the muramic acid assay. The fractions between
124 and 156 mL, which represented a relatively high-molecular-
weight fraction, containing PG were pooled, and the relatively
low-molecular-weight fraction was discarded.
The pooled fraction was loaded in 1-mL aliquots onto a
Superdex 200 column to remove contaminating protein. The
presence of PG in the eluted fractions was determined by
ELISA. During the column passage, the aliquots were diluted
25 times, and therefore the colorimetric muramic acid assay
was not sensitive enough to detect muramic acid. The protein
content of all fractions was measured by the Bradford method
[30]. Figure 3 shows the amount of protein and PG in all frac-
tions after Superdex 200 column gel ®ltration of 1 mL of the
extract.
The fractions to be used for in vitro studies should contain
minimal amounts of contaminating proteins. For this reason,
fractions with comparable amounts of protein were pooled.
This resulted in pooling of fractions 2±5 (P1), fractions 6±8
(P2), fractions 9±16 (P3), fraction 17 (P4), fractions 18±22 (P5),
and fractions 23±25 (P6). Fraction 23±25 (P6) was used as a
control, since this fraction did not contain PG or protein. After
all runs of the 7 spleens, the corresponding fractions were
pooled, dialyzed against Milli-Q water, lyophilized, and stored
at 2207C.
Protein analysis. After Sephadex and Superdex 200 gel ®l-
tration, the level of protein in the fractions was measured ac-
cording to Bradford [30]. With PG preparations of Eubacterium
aerofaciens and Brevibacterium divercatium, we showed that the
method according to Lowry et al. [31] was more sensitive to
detect protein (data not shown). Because the dilutions of the
pooled fractions used in some of the cytokine induction ex-
periments were based on protein concentrations, we used the
method of Lowry et al. (table 1). The results show that fractions
P1 and P4 contain the lowest levels of protein.
Muramic acid analysis by colorimetric muramic acid assay.
To determine the amount of PG in the pooled fractions, a
colorimetric muramic acid assay was performed. Results are
shown in table 1. Muramic acid could only be detected after
acid hydrolysis to remove peptides from PG, indicating that
PG present in human spleen is structurally mostly intact. In
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Figure 3. Separation of PG using Superdex 200 gel ®ltration. One milliliter of spleen extract after Sephadex gel ®ltration was added to Superdex
200 connected to fast-performance liquid chromatograph. Amount of protein (M) and PG (m) was measured in all fractions by Bradford method
[30] and ELISA, respectively. Pooled fractions: F2±F5 (P1), F6±F8 (P2), F9±F16 (P3), F17 (P4), F18±F22 (P5), and F23±F24 (P6) (↔).
Table 1. Protein and muramic acid content in pooled fractions iso-
lated from human spleen.
Fraction
Muramic acid (mg/mL) Protein (mg/mL)
Before
hydrolysis
After
hydrolysis
Bradford
method [30]
Lowry
method [31]
P1 0 70 0 63
P2 0 62 44 170
P3 ND ND 975 1300
P4 0 42 293 290
P5 0 56 34 75
P6 0 0 0 0
NOTE. Protein was measured according to Bradford [30] and Lowry et al.
[31]. Muramic acid was measured by colorimetric muramic acid assay. ND, not
done.
contrast, hydrolysis of PG isolated from human feces had no
effect on the level of muramic acid measured by the colorimetric
muramic acid assay. This indicates that PG in human feces
contains no or minimal levels of peptide chains bridging the
MurNac backbone. The colorimetric muramic acid assay could
not be used to measure the amount of PG in P3 because the
level of protein in the fraction was too high.
Muramic acid by HPLC analysis. To con®rm the presence
of PG in the fractions isolated from human spleen, P1 and P4
were analyzed for the presence of muramic acid using HPLC.
These two fractions were used because protein levels were low.
First, the fractions were applied to the column (®gure 4A) and
spiked by adding dansylated muramic acid to the fraction. The
peak with a retention time of 12.8 min was covered by muramic
acid added to the fraction (®gure 4B). This is also the retention
time of muramic acid when it is loaded onto the column on its
own. There are many peaks in the chromatogram, and therefore
the peak with retention time 12.8 min was collected and rean-
alyzed to assess whether it had the same retention time as the
standard dansyl muramic acid. The only peak in the chromato-
gram had the same retention time as dansyl muramic acid (®g-
ure 4C). This peak was spiked by adding muramic acid to the
sample. The smaller peak with retention time 5.4 min belonged
to the muramic acid added to the sample (®gure 4D). In the
PG fraction, we could not detect this peak because free dansyl
groups were detected after this retention time. These results
con®rm the presence of muramic acid in both fractions. Because
muramic acid is a unique component of PG, the HPLC analysis
also con®rmed the presence of PG in the fractions.
Induction of proinflammatory cytokines by PG. To inves-
tigate whether PG in human spleen tissue is biologically active,
production of TNF-a, IL-1, and IL-6 was measured in vitro
after incubation of human blood with PG isolated from human
spleen. Because P1 contained the lowest amount of contami-
nating protein, this fraction was used. TNF-a, IL-1, and IL-6
were produced after stimulation with PG (®gure 5). This pro-
duction was dose-dependent, correlating with the concentration
of P1 added to the blood cultures.
Polymyxin B is an ef®cient antagonist of LPS activity, thereby
inhibiting LPS-induced cytokine production. To exclude the
possibility that activity of PG isolated from human spleen is
due to contaminating LPS, we analyzed whether cytokine in-
duction by PG was blocked by polymyxin B. Production of
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Figure 4. Identi®cation of muramic acid in P5 isolated from human spleen. Reversed-phase high-performance liquid chromatography on C18
column (5 mm, mm) in discontinuous gradient 0%±15% methanol over 27 min at 1.0 mL/min of (A) hydrolyzed and dansylated preparation4 3 250
of P5 of spleen from patient 1; B was like A but spiked with dansylated muramic acid. C, Collected peak with retention time 12.8 min from
chromatogram A. D was like C but spiked with dansylated muramic acid. Absorbance was measured at 330 nm. Arrows indicate peak with
retention time 12.8 min, identi®ed as muramic acid. P1 (not shown) had same pattern.
TNF-a, IL-1, and IL-6 induced by P1 was not inhibited by
polymyxin B. LPS served as a positive control in all experi-
ments, and 1 ng/mL was able to induce the same level of cy-
tokines induced by P1 (75 ng/mL muramic acid). As expected,
LPS-driven induction of cytokines was inhibited by polymyxin
B. PG isolated from human feces also induced TNF-a, but the
concentration (based on the amount of muramic acid) needed
to induce the same level of cytokine production as P1 was 150
times higher.
To exclude the possibility that contaminating proteins present
in the P2±P6 fractions induced proin¯ammatory cytokine pro-
duction, P1±P6 was analyzed on the basis of equal protein
concentrations. The amount of protein was based on a 1:800
dilution of fraction P1 (75 ng/mL muramic acid). This fraction
contained 78 ng/mL protein (according to the Lowry assay).
All fractions were diluted, so the concentration of protein added
to the blood cells was 78 ng/mL. As expected, P6, which con-
tained no PG or protein, could not induce cytokine production
by whole blood cells; however, P1, P2, P4, and P5 all induced
cytokine production (table 2). P3 did not induce cytokine pro-
duction. Since P3 contains very high amounts of proteins, a
dilution to 78 ng of protein results in minimal traces of PG in
the fraction. This clearly suggests that contaminating protein
does not induce cytokine production. The levels of TNF-a, IL-
1, and IL-6 induced by the distinct fractions differed strongly
between fractions, indicating that protein present at equal con-
centrations in all fractions does not induce cytokine production.
Consistent with this, the cytokine production directly correlated
with the amount of PG in the fractions (correlation coef®cients
were 0.9, 0.8, and 0.9 for respective TNF-a, IL-1, and IL-6
production compared with the amount of PG in the fractions).
This indicates that PG, but not protein, present in the fractions
induces the production of TNF-a, IL-1, and IL-6 by human
blood cells.
To con®rm that PG and not contaminating proteins causes
the cytokine production, human blood cells were incubated with
anti-CD14 antibody for 30 min at 377C. All fractions were
diluted 80-fold, resulting in the following muramic acid con-
centrations: (P1) 88, (P2) 78, (P3) not done, (P4) 53, (P5) 70,
and (P6) 0 ng/mL. Anti-CD14 antibody blocked cytokine pro-
duction by the different fractions in a dose-dependent manner.
TNF-a production was completely blocked in all fractions and
LPS at a concentration of 10 mg/mL (®gure 6). An isotype-
matched control IgG2b antibody (MOPC-195) did not affect
cytokine production.
Discussion
In the current study, we show that structurally intact PG
isolated from sterile human spleen can induce production of
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Figure 5. Production of proin¯ammatory cytokines by human
blood cells after stimulation with PG isolated from human spleen.
Human blood cells were incubated for 5 h in presence of P1 with or
without polymyxin B. In supernatants, (A) tumor necrosis factor
(TNF)-a production measured by WEHI 164.13 in cytotoxicity assay.
B, Interleukin (IL)-1 production measured using IL-1±dependent sub-
line of T cell line D10.G4.1. C, IL-6 production measured using IL-
6±dependent murine hybridoma cell line B9. LPS, lipopolysaccharide.
Table 2. Production of tumor necrosis factor (TNF)-a and interleukin
(IL)-1 and -6 by human blood cells after stimulation by the different
fractions pooled after Superdex 200 gel ®ltration.
Fraction Muramic acid Protein TNF-a IL-1 IL-6
P1 75 78 290 5 25 35 5 4 853 5 80
P5 64 78 140 5 20 55 5 10 476 5 55
P2 28 78 64 5 7 15 5 2 123 5 12
P4 11 78 38 5 4 14 5 1 89 5 9
P3 ND 78 0 0 0
P6 0 0 0 0 0
Medium 0 0 0 0 0
NOTE. Human blood cells were incubated for 5 h with all pooled fractions
(P1±P6) diluted to protein concentration of 78 ng/mL. TNF-a, IL-1, and IL-6,
measured in supernatants by bioassays, are shown in U/mL; muramic acid and
protein are in ng/mL. ND, not done.
the proin¯ammatory cytokines TNF-a, IL-1, and IL-6 by hu-
man blood cells. Other studies have demonstrated the capacity
of cytokine induction by PG derived from bacterial cultures [9,
10], but the ability of PG present in human tissues to induce
cytokine production has not been reported.
PG is thought to play an important role in the immunologic
response against gram-positive infections, but it has also been
hypothesized to be involved in the pathogenesis of chronic in-
¯ammations like rheumatoid arthritis. Our group investigated
the role of PG derived from the normal intestinal ¯ora in the
pathogenesis of rheumatoid arthritis. The presence of PG in
several human tissues [18±23] suggests that the human body is
also constantly exposed to PG outside the gut. It is possible
that PG in human tissues other than the gut is derived from
normal intestinal ¯ora. That we can isolate 50 mg of PG per
100 g of feces shows that high amounts of PG are continuously
present in the intestine.
We hypothesize that PG is able to traverse the intestinal wall
by unknown mechanisms and gain access to other sites of the
body through the bloodstream or lymph circulation. PG is lo-
cated in antigen-presenting cells in tissues like human spleen
and lymph nodes and also in synovial tissues. This was shown
by immunohistochemical staining with a MAb against PG iso-
lated from human feces [23]. To investigate the relevance of PG
in human tissues, we studied the biologic activity of PG isolated
from human spleen. To obtain a high amount of PG, it was
necessary to modify the method described earlier [25]. Because
the passage of the spleen extract after Sephadex G25 gel ®l-
tration through a DEAE and Dowex column causes a consid-
erable loss of PG, we developed another method to extract the
protein. This was performed by size exclusion using Sephadex
G25 gel ®ltration followed by Superdex 200 gel ®ltration. Be-
cause the PG-containing fraction is diluted 25-fold by the Su-
perdex 200 column passage, the colorimetric muramic acid as-
say is not sensitive enough to detect PG in each fraction.
Therefore, we performed an ELISA using a MAb against PG
that is a more sensitive method to detect PG.
We used two methods to detect PG in pools P1±P6. The
HPLC analysis was used to con®rm the presence of muramic
acid in the fractions, leading to the conclusion that PG was
present. The colorimetric muramic acid assay was used to mea-
sure the amount of PG in the fractions. This method was also
used to determine whether PG is intact in terms of the presence
of peptide interlinks. This is important because earlier studies
show that the structure of PG is very crucial for its biologic
activity. For example, muramyl dipeptide is the minimal struc-
ture of PG that is biologically active, but a much higher amount
is needed compared with large molecules of PG that have a
repetitive nature [12]. Furthermore, PG isolated from the ileum,
which is mostly intact, can induce arthritis in rats. PG isolated
from feces that are not intact cannot induce arthritis in rats
[39]. This suggests that the structural integrity of PG is crucial
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Figure 6. Inhibition of tumor necrosis factor (TNF)-a production by human blood cells after incubation with anti-CD14 antibody. Human
blood cells were incubated with anti-CD14 antibody (5 and 10 mg/mL) for 30 min then stimulated with P1±P6 and lipopolysaccharide (LPS) for
5 h. TNF-a production measured by capture ELISA.
to its biologic activities. PG isolated from human spleen was
largely intact, because no muramic acid could be detected be-
fore hydrolysis. Analysis of PG isolated from human feces re-
vealed that the PG is not intact. With the improved puri®cation
of PG, we were able to isolate 1.9 mmol muramic acid per 100
g of spleen tissue. The amount of muramic acid isolated is
similar to that by the earlier described method [25] (2.3 mmol/
100 g spleen tissue), but the amount of protein in the fraction
is 20-fold lower, which means that the fraction is more suitable
for in vitro studies.
The cytokine induction assays show that PG isolated from
human spleen can induce induction of TNF-a, IL-1, and IL-
6. Kinetics of cytokine induction by PG was the same as of
LPS, but the amount of PG needed was 100 times higher than
with LPS. The fact that low amounts of PG isolated from
human spleen were required in comparison with PG from hu-
man feces indicates that intact PG is more active than a more
degraded form.
To exclude contamination of the isolated fraction, the sample
was analyzed using blood agar plates after every puri®cation
step. The whole procedure was also done with PBS. With this
procedure, we were unable to induce cytokine production (data
not shown). Contamination by LPS was excluded by incubating
the fractions with polymyxin B before the various PG prepa-
rations to the blood cells. No inhibition of the cytokine pro-
duction was found in contrast with cytokine induction by LPS.
The results show also that the levels of cytokine produced cor-
related with PG concentrations and not with protein concen-
trations, con®rming that PG is responsible for the cytokine
induction. This was con®rmed with fraction P3 that contained
very high concentrations of protein and unknown levels of PG.
After the sample was diluted to 78 ng/mL protein, no cytokine
production could be measured.
There are three other indications that the cytokines produced
by the different fractions are elicited by PG and not by con-
taminating proteins. First, the incubation of the spleen extract
in acetic acid at 1007C for 2 h will cause a loss of the tertiary
and secondary structure of the proteins. This will lead to a
reduction, if not a complete loss, of function of the proteins.
Second, the fact that TNF-a measured by ELISA could be
completely blocked in all fractions by incubating the human
blood cells with aCD14 also indicates that the proteins in the
fraction are not responsible for the cytokine production. CD14,
which is known as the LPS receptor, also binds PG and activates
cytokine production [11, 12]. Binding of proteins to CD14 me-
diating cytokine production has not been described. The third
indication that PG is responsible for the cytokine production
is that treatment of fraction P1±P6 with proteases (elastase,
trypsin, and a-chymoptrysin) does not affect cytokine produc-
tion. By using different concentrations of proteases (0.1±0.001%
vol/vol), cytokine induction was equal with and without treat-
ment (data not shown). The use of higher protease concentra-
tions was not possible because the proteases then induced cy-
tokine production directly. The inactivation of protein could
not be monitored by measuring the loss of proteins because the
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protein content of the proteases added to fractions was much
higher than of the original low level of contaminating proteins.
Various studies, including the present study, have shown that
PG is not restricted to the gut, even in the absence of infection.
In all 15 spleens we have obtained thus far, PG-containing cells
could be detected by use of immunohistochemistry. All spleens
used were removed during surgery, because this is the only way
to obtain sterile human spleens. These spleens were removed
for various reasons (including when the spleen was not dis-
eased), indicating that healthy people contain PG in their
spleens. It has been hypothesized that these bacterial products
are derived from the intestinal ¯ora. Because the present study
showed that PG in the human spleen is mostly intact, it is likely
that PG will pass the bowel wall before it is degraded by en-
zymes [39].
A prime question is whether the presence of PG in sterile
human spleen tissues has any biologic signi®cance. To answer
this question, it is important to know whether PG in human
tissues has biologic activity. This study shows that in vitro PG
has the capability to induce cytokine production by human
blood cells. If this activity also occurs in vivo, antigen-pre-
senting cells containing PG might be activated by PG to pro-
duce proin¯ammatory cytokines. The function of this cytokine
production is possibly the triggering of a continuous immune
response for controlling normal homeostasis. It was recently
argued that continuous exposure to bacterial antigens is im-
portant in regulation of Th1 versus Th2 CD4-positive T cells
[40]. Disturbance of this Th1-Th2 balance may lead to auto-
immune diseases. A possible way by which this balance can be
disturbed may be the presence of too much PG in tissues be-
cause of intestinal injury. The presence of PG in tissues where
the clearance of antigens is very dif®cult, for example synovial
tissue, could induce local in¯ammatory processes.
In conclusion, PG isolated from human spleen is largely in-
tact and can induce cytokine production by human blood cells
at very low concentrations. To further investigate whether PG-
containing cells in vivo can also induce proin¯ammatory cy-
tokine production in situ, these cells will be analyzed by im-
munohistochemistry. In addition, immunization of mice with
PG will allow kinetic analysis of local cytokine induction by
splenic antigen-presenting cells containing PG.
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